Targeting entry into mitochondria for increased anticancer efficacy of BCL-XL-selective inhibitors in lung cancer
The BCL-XL-selective inhibitors exhibit potential clinical application value when combined with chemotherapeutic drugs for the treatment of solid tumors. However, their efficacy in these settings is still low when treated with BCL-XL inhibitors alone in solid tumors. The mechanism responsible for th...
Saved in:
Main Authors: | Liangping Li (Author), Pingping Li (Author), Huanhuan Song (Author), Xuesong Ma (Author), Shulan Zeng (Author), Yan Peng (Author), Guohai Zhang (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2022-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
MDM2-BCL-XL PROTACs enable degradation of BCL-XL and stabilization of p53
by: Mengyang Chang, et al.
Published: (2022) -
PROTACs are effective in addressing the platelet toxicity associated with BCL-XL inhibitors
by: Peiyi Zhang, et al.
Published: (2020) -
Bcl-XL but Not Bcl-2 Is a Potential Target in Medulloblastoma Therapy
by: Mike-Andrew Westhoff, et al.
Published: (2022) -
BCL-xL is correlated with disease severity in neonatal infants with early sepsis
by: Wu Wenshen, et al.
Published: (2021) -
Bcl-xL activity influences outcome of the mitotic arrest
by: M. Suleimenov, et al.
Published: (2022)